The decline of the immune system with age (immunosenescence) is reflected in the increased susceptibility to infectious diseases,
poorer response to vaccination, increased prevalence of cancer, accelerated aging (frailty), autoimmune and other chronic diseases.
On the basis of the current studies as well as previous reports on the use of intradermal immunization against influenza, hepatitis B, rabies, and other infectious diseases, 2,3,8 it is becoming clear that use of the intradermal route may at least partially overcome the relatively
poor influenza - specific immune
responses seen in certain at - risk populations, particularly the elderly, in whom the immune
response in general is known
to diminish with age.9 Moreover, in times of shortage, the dose - sparing intradermal approach might be particularly well suited
to the young, healthy persons included in the CDC's high - priority group for
vaccination, such as health care workers, as well as
to younger, otherwise healthy populations in general.